Download pdf
Klotho in Alzheimer's Disease: Evaluating Therapeutic Potential and Addressing Experimental Challenges
- 1 Department of Biochemistry, University of Toronto, Toronto, M5S 1A, Canada
- 2 College of pharmacy, Nanjing University of Chinese Medicine, Taizhou, 225500, China
* Author to whom correspondence should be addressed.
Abstract
Alzheimer's Disease (AD), the most common neurodegenerative disorder, is characterized by cognitive decline and neurodegeneration. This review explores the intersection of AD pathology and Klotho, a protein linked to aging and cognitive enhancement. Klotho modulates aging-related processes, including amyloid-beta dynamics and neuroinflammation, through mechanisms such as autophagy enhancement, oxidative stress reduction, and amyloid-beta clearance. Research has indicated Klotho's potential in mitigating AD symptoms in murine models, such as APP/PS1. However, methodological challenges, including variability in experimental models and inconsistencies in Klotho administration, complicate the translation of these findings. This review synthesizes current research, highlights experimental limitations, and proposes methodological improvements to enhance the reliability and applicability of Klotho as a therapeutic target for AD, providing a foundation for future investigations that could revolutionize neurodegenerative disease management.
Keywords
Klotho, Alzheimer's Disease, Neuroinflammation, Autophagy, Experimental Design
[1]. Ising C., Venegas C., Zhang S., Scheiblich H., Schmidt S.V., Vieira-Saecker A., Schwartz S., Albasset S., McManus R.M., Tejera D., et al. (2019) NLRP3 inflammasome activation drives tau pathology. Nature. 575:669–673.
[2]. Nalivaeva, N. N., & Turner, A. J. (2019). Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy. British Journal of Pharmacology, 176(18), 3447–3463.
[3]. Hansen D.V., Hanson J.E., Sheng M. (2018) Microglia in Alzheimer’s disease. J. Cell Biol. 217:459–472. doi: 10.1083/jcb.201709069.
[4]. Deane R., Bell R.D., Sagare A., Zlokovic B.V. (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease. CNS Neurol. Disord. Drug Targets. 8:16–30.
[5]. Chiu, C., Miller, M. C., Monahan, R., Osgood, D. P., Stopa, E. G., & Silverberg, G. D. (2015). P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations. Neurobiology of aging, 36(9), 2475–2482.
[6]. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., Iwasaki, H., Iida, A., Shiraki-Iida, T., Nishikawa, S., Nagai, R., & Nabeshima, Y. I. (1997). Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 390(6655), 45–51.
[7]. Tan M.S., Yu J.T., Jiang T., Zhu X.C., Tan L. (2013) The NLRP3 inflammasome in Alzheimer’s disease. Mol. Neurobiol. 48:875–882.
[8]. Zhao, Y., Zeng, C. Y., Li, X. H., Yang, T. T., Kuang, X., & Du, J. R. (2020). Klotho overexpression improves amyloid-β clearance and cognition in the APP/PS1 mouse model of Alzheimer's disease. Aging cell, 19(10), e13239.
[9]. Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020). Cerebral amyloid angiopathy and Alzheimer disease – One peptide, two pathways. Nature Reviews Neurology, 16(1), 30–42.
[10]. Fung, T. Y., Iyaswamy, A., Sreenivasmurthy, S. G., Krishnamoorthi, S., Guan, X. J., Zhu, Z., Su, C. F., Liu, J., Kan, Y., Zhang, Y., Wong, H. L. X., & Li, M. (2022). Klotho an Autophagy Stimulator as a Potential Therapeutic Target for Alzheimer's Disease: A Review. Biomedicines, 10(3), 705.
[11]. Dubal, D. B., Zhu, L., Sanchez, P. E., Worden, K., Broestl, L., Johnson, E., Ho, K., Yu, G. Q., Kim, D., Betourne, A., Kuro-O, M., Masliah, E., Abraham, C. R., & Mucke, L. (2015). Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. The Journal of neuroscience: the official journal of the Society for Neuroscience, 35(6), 2358–2371.
[12]. Massó, A., Sánchez, A., Gimenez-Llort, L., Lizcano, J. M., Cañete, M., García, B., Torres-Lista, V., Puig, M., Bosch, A., & Chillon, M. (2015). Secreted and Transmembrane αKlotho Isoforms Have Different Spatio-Temporal Profiles in the Brain during Aging and Alzheimer's Disease Progression. PloS one, 10(11), e0143623.
[13]. Zeng, C. Y., Yang, T. T., Zhou, H. J., Zhao, Y., Kuang, X., Duan, W., & Du, J. R. (2019). Lentiviral vector-mediated overexpression of Klotho in the brain improves Alzheimer's disease-like pathology and cognitive deficits in mice. Neurobiology of Aging, 78, 18–28.
[14]. Castner, S. A., Gupta, S., Wang, D., Moreno, A. J., Park, C., Chen, C., Poon, Y., Groen, A., Greenberg, K., David, N., Boone, T., Baxter, M. G., Williams, G. V., & Dubal, D. B. (2023). Longevity factor klotho enhances cognition in aged nonhuman primates. Nature aging, 3(8), 931–937.
[15]. Aykac, A., & Sehirli, A. Ö. (2021). The Function and Expression of ATP-Binding Cassette Transporters Proteins in the Alzheimer's Disease. Global medical genetics, 8(4), 149–155.
[16]. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., et al. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Investig. 118:671–682.
[17]. Hanson, K., Fisher, K., & Hooper, N. M. (2021). Exploiting the neuroprotective effects of α-klotho to tackle ageing- and neurodegeneration-related cognitive dysfunction. Neuronal signaling, 5(2), NS20200101.
Cite this article
Chen,E.Y.;Zhu,S. (2025). Klotho in Alzheimer's Disease: Evaluating Therapeutic Potential and Addressing Experimental Challenges. Theoretical and Natural Science,78,60-66.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).